Teva and Alvotech strike deal for ‘increased involvement’ at Alvotech’s troubled Iceland site

Te­va is tak­ing Alvotech’s man­u­fac­tur­ing trou­bles in­to its own hands af­ter de­fi­cien­cies at an Ice­landic fa­cil­i­ty led to an­oth­er re­jec­tion for the part­ners’ Hu­mi­ra biosim­i­lar last month.

The ex­pand­ed part­ner­ship an­nounced Mon­day in­cludes “in­creased in­volve­ment by Te­va re­gard­ing man­u­fac­tur­ing and qual­i­ty at Alvotech’s man­u­fac­tur­ing fa­cil­i­ty,” the com­pa­nies said in a press re­lease.

The FDA turned down the com­pa­nies’ in­ter­change­able Hu­mi­ra biosim­i­lar can­di­date AVT02 twice this year. A Te­va spokesper­son con­firmed to End­points News that those re­jec­tions were be­hind the gener­ics gi­ant’s greater in­volve­ment. In June, reg­u­la­tors not­ed “cer­tain de­fi­cien­cies” at Alvotech’s Reyk­javik fa­cil­i­ty in a com­plete re­sponse let­ter, ac­cord­ing to Alvotech. The com­pa­ny gave a sim­i­lar ex­pla­na­tion up­on the drug’s pri­or re­jec­tion in April.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN